ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hip OA

Apremilast Effective for Psoriatic Arthritis

Reuters Staff  |  February 2, 2016

NEW YORK (Reuters Health)—Apremilast improves clinical outcomes in patients with psoriatic arthritis and active psoriasis, according to results from the PALACE 3 randomized controlled trial. Apremilast, a phosphodiesterase 4 (PDE4) inhibitor, showed efficacy against psoriatic arthritis in the PALACE 1 trial. Dr. Christopher J. Edwards from University Hospital Southampton in the U.K. and colleagues evaluated…

Filed under:ConditionsDrug UpdatesPsoriatic Arthritis Tagged with:apremilastPsoriasispsoriatic arthritis

1% of U.S. Doctors Responsible for a Third of Malpractice Payments

Gene Emery  |  February 1, 2016

(Reuters Health)—Just one out of every 100 U.S. doctors is responsible for 32% of the malpractice claims that result in payments to patients, according to a comprehensive study of 15 years’ worth of cases. And when a doctor has to pay out one claim, the chances are good that the same physician will soon be…

Filed under:Practice SupportProfessional Topics Tagged with:malpracticeMedical MalpracticeNational Practitioner Data Bankpayment

Researchers Target Altered T Cell Metabolism in SLE to Reverse Lupus Immuno-Phenotype

Lara C. Pullen, PhD  |  February 1, 2016

A recent study on systemic lupus erythematosus examined the effects of metabolic modulators on the disease’s abnormal T cell metabolism. Using a combination therapy of metformin and 2-deoxy-D-glucose, researchers were able to normalize CD4+ T cell functions and restore defective IL-2 production in mice…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:CD4metabolismT cell

VA Musculoskeletal Education Pilot Program Helps PCPs Treat Patients

Arthritis Care & Research  |  January 27, 2016

To improve access to quality of care for patients with osteoarthritis and other musculoskeletal pain, the U.S. Department of Veterans Affairs (VA) launched a continuing education program designed to strengthen the musculoskeletal knowledge and skills of primary care providers (PCPs). In the program’s initial trial in 2012, 19 physicians were trained on exams, treatments and joint injections. Two years after course completion, some participants increased the number of intraarticular corticosteroid injections at their clinics without needing to refer patients to specialists…

Filed under:Career DevelopmentEducation & TrainingOsteoarthritis and Bone DisordersProfessional TopicsResearch Rheum Tagged with:Arthritis Care & ResearchDepartment of Veteran Affairsjoint injectionMusculoskeletalmusculoskeletal conditionsOsteoarthritispilot

Large Group Study of Systemic JIA Patients Provides Insight into Disease Pathology

Lara C. Pullen, PhD  |  January 25, 2016

In a large group genetic analysis, researchers identified an association between the class II HLA region, including HLA-DRB1*11, and systemic juvenile idiopathic arthritis (sJIA), implicating adaptive immune molecules in sJIA’s pathogenesis and reinforcing its unique genetic position among JIA subtypes…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:geneticjuvenile idiopathic arthritis (JIA)systemic juvenile idiopathic arthritis

How to Avoid Legal Pitfalls

Richard Quinn  |  January 22, 2016

In busy rheumatology practices, mountains of paperwork for insurance companies and federal healthcare programs make it hard to keep track of what’s legal. Missing documentation is the most common way to spark an investigation. Here are a few considerations to help you avoid legal pitfalls…

Filed under:Billing/CodingLegal UpdatesPractice SupportProfessional Topics Tagged with:American College of Rheumatology (ACR)Anti-Kickback StatuteDepartment of JusticeLegalMedicarePractice ManagementStark Law

Patients Are Essential to Grassroots Advocacy

Kelly Weselman, MD  |  January 20, 2016

In 2015, ACR members were powerful advocates on important issues affecting public health and rheumatology. But we should not forget about an important resource—patients, each of whom can bring unique perspectives to legislators in Washington, D.C. Working together, our voices are stronger. Here’s how your patients can work with the ACR to advocate for their health and rheumatology…

Filed under:From the CollegeLegislation & AdvocacyProfessional Topics Tagged with:Advocates for ArthritisAmerican College of Rheumatology (ACR)patientSimple Tasks

FDA Approves New Drugs for Pain

Michele B. Kaufman, PharmD, BCGP  |  January 19, 2016

FDA Updates Belbuca, buccal-administered buprenorphine, has received U.S. Food and Drug Administration (FDA) approval for treating severe chronic pain.1 The dosage form is a dissolving film that is absorbed through the inner lining of the cheek for chronic pain management. It’s expected to be commercially available in the first quarter of 2016. Seven dosage strengths…

Filed under:AnalgesicsDrug Updates Tagged with:DrugsFDAOsteoarthritisPainrheumatologySafety

Rheumatologists on the Move, January 2016

Ann-Marie Lindstrom  |  January 19, 2016

2015 Mary Betty Stevens Young Investigator Prize Awarded to Dr. Timothy Niewold Timothy B. Niewold, MD, Mayo Clinic rheumatologist and associate professor of medicine at the Mayo Clinic College of Medicine, Rochester, Minn., was awarded the 2015 Mary Betty Stevens Young Investigator Prize at a reception held during the 2015 ACR/ARHP Annual Meeting in San…

Filed under:Career DevelopmentProfessional TopicsProfiles Tagged with:Career developmentProfilesrheumatologist

Ethics Forum: Physicians Face Ethical Quandary Discussing Poor Prognosis with Patients

Rashmi Shah, MD, Jennifer Barton, MD, & Robert H. Shmerling, MD  |  January 19, 2016

Over the course of a month, you diagnose systemic sclerosis in two newly evaluated patients. Their responses to the news could not be more different. Patient 1 is a previously healthy 55-year-old man who is an avid bicyclist and skier. He presents with a several-month history of rapidly progressive skin tightening extending to the proximal…

Filed under:EthicsPractice SupportProfessional Topics Tagged with:Ethicspatient communicationphysicianprognosis

  • « Previous Page
  • 1
  • …
  • 233
  • 234
  • 235
  • 236
  • 237
  • …
  • 337
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences